Patisiran

Should be administered by a healthcare professional. Required premedication (§2.2): all patients receive, at least 60 minutes before the start of the infusion on the day of infusion — intravenous corticosteroid (e.g. dexamethasone 10 mg, or equivalent), oral acetaminophen/paracetamol 500 mg, intravenous H1 blocker (e.g. diphenhydramine 50 mg, or equivalent) and intravenous H2 blocker (e.g. famotidine 20 mg, or equivalent); equivalents may be given orally if the intravenous form is unavailable or not tolerated. For patients tolerating infusions but experiencing adverse reactions related to the corticosteroid, the corticosteroid may be reduced in 2.5 mg increments to a minimum of 5 mg dexamethasone intravenously, or equivalent; some patients may require additional or higher premedication doses. Missed dose: administer as soon as possible; if given within 3 days of the missed dose continue the original schedule, if given more than 3 days after the missed dose continue every 3 weeks thereafter. The infusion duration may be extended in the event of an infusion-related reaction. Supplement with the recommended daily allowance of vitamin A (treatment reduces serum vitamin A levels); refer to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur. Elderly: no dose adjustment is required in patients aged 65 years or older. No dedicated drug-interactions section was captured in the fetched label — verify against UK SPC §4.5. Paediatric use: the US label states safety and effectiveness in paediatric patients have not been established — no paediatric dose is given; verify any paediatric use against a children's formulary and specialist protocol. No UK SPC (eMC) record was present in the source bundle — this dose is from US prescribing information and must be verified against UK labelling.